Daxor Corporation

NasdaqCM DXR

Daxor Corporation Capital Expenditure for the Trailing 12 Months (TTM) ending June 30, 2024

Daxor Corporation Capital Expenditure is NA for the Trailing 12 Months (TTM) ending June 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: DXR

Daxor Corporation

CEO	Mr. Michael Richard Feldschuh
IPO Date	July 25, 1983
Location	United States
Headquarters	109 Meco Lane
Employees	37
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Clinical Trials Pharmaceuticals

Description

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Key trends

Past 5 years